| 58.85 0.06 (0.1%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 83.52 | 1-year : | 92.99 |
| Resists | First : | 71.51 | Second : | 79.62 |
| Pivot price | 65.81  |
|||
| Supports | First : | 58.4 | Second : | 48.58 |
| MAs | MA(5) : | 61.36 |
MA(20) : | 67.22 |
| MA(100) : | 65.07 |
MA(250) : | 73.06 |
|
| MACD | MACD : | -1.3 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8.5 |
D(3) : | 13.8 |
| RSI | RSI(14): 36  |
|||
| 52-week | High : | 100.76 | Low : | 56.04 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EXAS ] has closed above bottom band by 16.5%. Bollinger Bands are 100.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 60.34 - 60.64 | 60.64 - 60.94 |
| Low: | 57.76 - 58.06 | 58.06 - 58.37 |
| Close: | 58.36 - 58.84 | 58.84 - 59.33 |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Thu, 25 Apr 2024
Exact Sciences Announces Board Member Retirement - TipRanks.com - TipRanks
Wed, 24 Apr 2024
Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note - Zacks Investment Research
Wed, 24 Apr 2024
Here's Why Baron Health Care Fund Reduced Exact Sciences Corporation (EXAS) - Yahoo Finance
Tue, 23 Apr 2024
Here's Why Investors Should Hold Exact Sciences (EXAS) Stock - Yahoo Movies UK
Mon, 22 Apr 2024
Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings? - Yahoo Finance
Wed, 17 Apr 2024
Exact Sciences Corporation's (NASDAQ:EXAS) Profit Outlook - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 182 (M) |
| Held by Insiders | 1.7956e+008 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 7,040 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0223e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -0.8 % |
| Operating Margin | -8.2 % |
| Return on Assets (ttm) | -12 % |
| Return on Equity (ttm) | -3.1 % |
| Qtrly Rev. Growth | 2.5e+009 % |
| Gross Profit (p.s.) | 13.82 |
| Sales Per Share | -5.37 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 156 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 16 |
| Price to Book value | 0 |
| Price to Sales | -10.97 |
| Price to Cash Flow | 4.17 |
| Dividend | 0 |
| Forward Dividend | 6.34e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|